Nocturnal oximetry for the diagnosis of the sleep apnoea hypopnoea syndrome: a method to reduce the number of polysomnographies?

E Chiner, J Signes-Costa, JM Arriero, J Marco… - Thorax, 1999 - thorax.bmj.com
BACKGROUND Polysomnography (PSG) is currently the “gold standard” for the diagnosis
of the sleep apnoea hypopnoea syndrome (SAHS). Nocturnal oximetry (NO) has been used …

Outcome of bone marrow transplantation patients requiring mechanical ventilation

…, SA Giralt, J Blanco, J Signes-Costa… - Critical care …, 2000 - journals.lww.com
Objective: To identify outcome predictors in bone marrow transplantation (BMT) patients
admitted to the intensive care unit (ICU) of The University of Texas MD Anderson Cancer Center …

[HTML][HTML] ROX index as predictor of high flow nasal cannula therapy success in acute respiratory failure due to SARS-CoV-2

…, A Mulet, A Quezada, P Royo, J Signes-Costa - Respiratory …, 2021 - Elsevier
Background High-Flow Nasal Cannula (HFNC) therapy is useful treatment in patients with
acute respiratory failure (ARF). The ROX index (ratio of pulse oximetry/fraction of inspired …

Official Statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) on electronic cigarettes and IQOS®

J Signes-Costa, JI de Granda-Orive, ÁR Pinedo… - Archivos de …, 2019 - Elsevier
The use of novel tobacco products, particularly the electronic cigarette (EC) and partial
tobacco combustion devices (HnB systems: Heat not Burn), has increased exponentially, …

[HTML][HTML] Lung fibrosis and fibrosis in the lungs: is it all about myofibroblasts?

E Ortiz-Zapater, J Signes-Costa, P Montero, I Roger - Biomedicines, 2022 - mdpi.com
In the lungs, fibrosis is a growing clinical problem that results in shortness of breath and can
end up in respiratory failure. Even though the main fibrotic disease affecting the lung is …

[HTML][HTML] Lung function and radiological findings 1 year after COVID-19: a prospective follow-up

…, JB Soriano, J Signes-Costa - Respiratory …, 2022 - Springer
Background The coronavirus disease (COVID-19) pandemic has already affected more than
400 million people, with increasing numbers of survivors. These data indicate that a myriad …

SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients

…, J Buesa, A Marina, ML Blasco, J Signes-Costa… - Journal of Clinical …, 2020 - Elsevier
Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic
events in COVID-19 patients has been suggested. By using several experimental …

SARS‐CoV‐2‐reactive interferon‐γ‐producing CD8+ T cells in patients hospitalized with coronavirus disease 2019

…, MJ Forner, J Redon, J SignesCosta… - Journal of medical …, 2021 - Wiley Online Library
There is limited information on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
T‐cell immune responses in patients with coronavirus disease 2019 (COVID‐19). Both …

Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia

…, J Navarro, J Noceda, J Redon, J Signes-Costa… - medRxiv, 2020 - medrxiv.org
There is scarce information on the frequency of co-detection of respiratory pathogens (RP) in
patients with Covid-19. Documentation of coinfections in Covid-19 pneumonia patients may …

Prevalence and 30-day mortality in hospitalized patients with Covid-19 and prior lung diseases

J Signes-Costa, IJ Nunez-Gil, JB Soriano… - Archivos de …, 2021 - Elsevier
Introduction Patients with pre-existing respiratory diseases in the setting of COVID-19 may
have a greater risk of severe complications and even death. Methods A retrospective, …